Positive HER2 status - Is it a discriminating factor for disease outcome in steroid receptor-positive early breast cancer patients treated with adjuvant endocrine therapy only?

被引：1
|
作者：
Susnjar, S. [1 ]
Vujasinovic, T. [2 ]
Abu Rabi, Z. [2 ]
Neskovic-Konstantinovic, Z. [1 ]
Milovanovic, Z. [3 ]
Jovanovic, D. [3 ]
Gavrilovic, D. [4 ]
Borojevic, N. [5 ]
机构：
[1] Inst Oncol & Radiol Serbia, Dept Med Oncol, Belgrade, Serbia
[2] Inst Oncol & Radiol Serbia, Expt Oncol Lab, Belgrade, Serbia
[3] Inst Oncol & Radiol Serbia, Dept Pathol, Belgrade, Serbia
[4] Inst Oncol & Radiol Serbia, Ctr Data, Belgrade, Serbia
[5] Inst Oncol & Radiol Serbia, Dept Radiotherapy, Belgrade, Serbia
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70187-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [31] Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men
    Venigalla, Sriram
    Carmona, Ruben
    Guttmann, David M.
    Jain, Varsha
    Freedman, Gary M.
    Clark, Amy S.
    Shabason, Jacob E.
    JAMA ONCOLOGY, 2018, 4 (10)
  • [32] Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
    Larsen, Mathilde S.
    Bjerre, Karsten
    Lykkesfeldt, Anne E.
    Giobbie-Hurder, Anita
    Laenkholm, Anne-Vibeke
    Henriksen, Katrine L.
    Ejlertsen, Bent
    Rasmussen, Birgitte B.
    BREAST, 2012, 21 (05): : 662 - 668
  • [33] Updates on Adjuvant Therapy for Early Stage Hormone Receptor-Positive Breast Cancer
    Cavalcante, Ludimila L.
    Santa-Maria, Cesar A.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (12) : 18 - 23
  • [34] The relationship of positive steroid receptor (SR) status with disease outcome in patients treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil (A-CMF) chemotherapy (CHT) and adjuvant endocrine therapy
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 156 - 157
  • [35] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
    Johnston, Stephen R. D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
  • [36] HER2 and hormone receptor-positive breast cancer—blocking the right target
    Javier Cortés
    Cristina Saura
    Meritxell Bellet
    Eva Muñoz-Couselo
    Natalia Ramírez-Merino
    Virginia Calvo
    Jose Pérez
    María Vidal
    Nature Reviews Clinical Oncology, 2011, 8 : 307 - 311
  • [37] Pathologic response to neoadjuvant therapy in HER2 positive/oestrogen receptor positive breast cancer patients
    Gasol Cudos, A.
    Morales, S.
    Rodriguez Galindo, A.
    Velasco Sanchez, A.
    Serrate Lopez, A.
    Mele Olive, J.
    Canosa Morales, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S333 - S333
  • [38] The impact of circulating tumor cells on treatment response in early breast cancer patients with hormone receptor-positive and HER2 positive who underwent the neoadjuvant therapy
    Bae, Soong June
    Park, Soeun
    Cha, Chi Hwan
    Kim, Dooreh
    Lee, Janghee
    Ahn, Sung Gwe
    Jeong, Joon
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 78 - 79
  • [39] Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab
    McGuire, Andrew
    Kalinina, Olga
    Holian, Emma
    Curran, Catherine
    Malone, Carmel A.
    McLaughlin, Ray
    Lowery, Aoife
    Brown, James A. L.
    Kerin, Michael J.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (01) : 221 - 229
  • [40] Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab
    Andrew McGuire
    Olga Kalinina
    Emma Holian
    Catherine Curran
    Carmel A. Malone
    Ray McLaughlin
    Aoife Lowery
    James A. L. Brown
    Michael J. Kerin
    Breast Cancer Research and Treatment, 2017, 164 : 221 - 229
12345